AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03355027
Drug: Alirocumab 150 MG/ML
RxNorm normalized name: alirocumab 150 MG/ML
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing to be performed by subcutaneous injection in clinic
Trial: NCT03355027
Drug: Ezetimibe 10Mg Tablet
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be instructed to take once daily at night.
Trial: NCT01181830
Drug: magnesium pidolate
RxNorm normalized name: magnesium pidolate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 8.1 mmol bid of magnesium pidolate
Trial: NCT02151149
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02151149
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00057941
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00057941
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00057941
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intramuscularly
Trial: NCT03232957
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal morphine
Trial: NCT03232957
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 isobaric bupivacaine
Trial: NCT01943292
Drug: Defactinib
RxNorm normalized name: Defactinib
DrugBank: Defactinib (DB12282)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00715988
Drug: Methadone HCl Inject 10 mg/ml (will require dilution)
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
Trial: NCT00715988
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
Trial: NCT03310593
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol as active intervention.
Trial: NCT01002703
Drug: Lenalidomide, Bendamustine, Prednisone
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
Trial: NCT04407000
Drug: Reference: Favipiravir 200 mg (Avigan)
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Reference Drug
Trial: NCT00452543
Drug: acamprosate
RxNorm normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
Trial: NCT03355027
Drug: Atorvastatin 40Mg Tablet
RxNorm normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Trial: NCT02156596
Drug: IV NSAI
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
Trial: NCT02156596
Drug: NM
RxNorm normalized name: NMP
DrugBank: Methyl pyrrolidone (DB12521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
Trial: NCT00452543
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
Trial: NCT00965731
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
Trial: NCT00965731
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
Trial: NCT00965731
Drug: PF-02341066
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
Trial: NCT00638378
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 25 mg tablets taken with water twice a day.
Trial: NCT00996216
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
Trial: NCT01098539
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
Trial: NCT01852110
Drug: MK-7622
RxNorm normalized name: MK-7622
DrugBank: MK-7622 (DB12897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7622 capsule
Trial: NCT03024801
Drug: autologous platelet-rich plasma
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
Trial: NCT01265732
Drug: PF-04191834
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, 100mg, dispersion
Trial: NCT01265732
Drug: PF-04191834
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, 100mg, suspension
Trial: NCT01265732
Drug: PF-04191834
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, 300mg, suspension
Trial: NCT00709514
Drug: DCB-WH1 ointment
RxNorm normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCB-WH1 ointment (1.25%), topically applied twice daily
Trial: NCT00254813
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04714515
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An FDA approved medicine to treat asthmatic patients
Trial: NCT00193323
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00193323
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01616524
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 400 mg, Twice daily, 24 weeks
Trial: NCT01616524
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 400 mg, Twice daily, 12 weeks
Trial: NCT01616524
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 60 mg, Once daily, 12 weeks
Trial: NCT01616524
Drug: Placebo matching Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks
Trial: NCT00939523
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All participants will be asked to take Lapatinib daily for six months during the research study.
Trial: NCT04714515
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An FDA approved antiarthritis drug
Trial: NCT04714515
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An FDA approved anti-parasitic medicine
Trial: NCT01539057
Drug: Fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts
Trial: NCT01539057
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
Trial: NCT00299455
Drug: amoxicillin-clavulanate
RxNorm normalized name: amoxicillin-clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
Trial: NCT03108833
Drug: Recombinant Human Prourokinase
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug is used for intravenous thrombolysis therapy
Trial: NCT03108833
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug is used for intravenous thrombolysis therapy
Trial: NCT02199379
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
Trial: NCT02026479
Drug: Dexamethasone Phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg; postauricular injection
Trial: NCT02026479
Drug: Dexamethasone Phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg; postauricular injection
Trial: NCT02031666
Drug: JNJ-56021927 capsule
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
Trial: NCT02031666
Drug: JNJ-56021927 tablet
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
Trial: NCT01204853
Drug: Sitaxentan
RxNorm normalized name: Sitaxentan
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: sitaxentan sodium 100 mg
Trial: NCT00391404
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg weekly (oral)
Trial: NCT02085317
Drug: sodium nitroprusside Iontophoresis
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
Trial: NCT00135603
Drug: amoxicillin/clavulanate potassium
RxNorm normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Clavulanic acid (DB00766)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
Trial: NCT00721487
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
Trial: NCT03790137
Drug: Fenfluramine Hydrochloride
RxNorm normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
Trial: NCT00111137
Drug: rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
Trial: NCT00111137
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
Trial: NCT03608501
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib capsules.
Trial: NCT03608501
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide capsules.
Trial: NCT03608501
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone tablets.
Trial: NCT02287272
Drug: CHF 5993 pMDI
RxNorm normalized name: CHF-6333
DrugBank: CHF-6333 (DB17815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
Trial: NCT02287272
Drug: Cimetidine plus CHF5993 pMDI
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
Trial: NCT01062360
Drug: Pseudoephedrine
RxNorm normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Trial: NCT00760578
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily, oral
Trial: NCT00760578
Drug: MSDC-0160 90 mg
RxNorm normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral
Trial: NCT00760578
Drug: MSDC-0160 220 mg
RxNorm normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral
Trial: NCT01338792
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01338792
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01324284
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
Trial: NCT02117726
Drug: Dexmedetomidine,midazolam
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02117726
Drug: Propofol,midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02848079
Drug: combined TAS-102 and TAS-OX
RxNorm normalized name: Ta
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
Trial: NCT02989194
Drug: VIS410 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intravenous fixed low dose of VIS410
Trial: NCT02989194
Drug: VIS410 high dose
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous fixed high dose of VIS410
Trial: NCT03111901
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab solution
Trial: NCT03111901
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 solution
Trial: NCT02024633
Drug: icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
Trial: NCT02024633
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Trial: NCT03355027
Drug: Atorvastatin 80Mg Tablet
RxNorm normalized name: atorvastatin 80 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Trial: NCT00141505
Drug: Bifeprunox
RxNorm normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02583698
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03912285
Drug: Amlodipine10mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 10mg will be administered orally twice a day for 9 days
Trial: NCT03912285
Drug: Losartan potassium 100mg
RxNorm normalized name: LOSARTAN POTASSIUM 100MG TAB
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 100mg will be administered orally once a day for 9 days
Trial: NCT03912285
Drug: Amlodipine plus Losartan
RxNorm normalized name: losartan and amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan